457 related articles for article (PubMed ID: 33202419)
21. Anti-SARS-CoV-2 hyperimmune plasma workflow.
Annamaria P; Eugenia Q; Paolo S
Transfus Apher Sci; 2020 Oct; 59(5):102850. PubMed ID: 32540345
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
Duan K; Liu B; Li C; Zhang H; Yu T; Qu J; Zhou M; Chen L; Meng S; Hu Y; Peng C; Yuan M; Huang J; Wang Z; Yu J; Gao X; Wang D; Yu X; Li L; Zhang J; Wu X; Li B; Xu Y; Chen W; Peng Y; Hu Y; Lin L; Liu X; Huang S; Zhou Z; Zhang L; Wang Y; Zhang Z; Deng K; Xia Z; Gong Q; Zhang W; Zheng X; Liu Y; Yang H; Zhou D; Yu D; Hou J; Shi Z; Chen S; Chen Z; Zhang X; Yang X
Proc Natl Acad Sci U S A; 2020 Apr; 117(17):9490-9496. PubMed ID: 32253318
[TBL] [Abstract][Full Text] [Related]
23. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A
Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412
[TBL] [Abstract][Full Text] [Related]
24. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
[TBL] [Abstract][Full Text] [Related]
25. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
Front Immunol; 2021; 12():711915. PubMed ID: 34276706
[TBL] [Abstract][Full Text] [Related]
26. Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.
Weisser M; Khanna N; Hedstueck A; Sutter ST; Roesch S; Stehle G; Sava M; Deigendesch N; Battegay M; Infanti L; Holbro A; Bassetti S; Pargger H; Hirsch HH; Leuzinger K; Kaiser L; Vu DL; Baur K; Massaro N; Busch MP; Simmons G; Stone M; Felgner PL; de Assis RR; Khan S; Tsai CT; Robinson PV; Seftel D; Irsch J; Bagri A; Buser AS; Corash L
Transfusion; 2022 Oct; 62(10):1997-2011. PubMed ID: 36054476
[TBL] [Abstract][Full Text] [Related]
27. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM
Trials; 2021 May; 22(1):323. PubMed ID: 33947446
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants.
Bellusci L; Golding H; Khurana S
J Clin Invest; 2023 Apr; 133(8):. PubMed ID: 36821375
[No Abstract] [Full Text] [Related]
29. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
[TBL] [Abstract][Full Text] [Related]
30. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
[TBL] [Abstract][Full Text] [Related]
31. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19.
Al-Tawfiq JA; Arabi Y
Hum Vaccin Immunother; 2020 Dec; 16(12):2973-2979. PubMed ID: 32881641
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report.
De Rienzo M; Foddai ML; Conti L; Mandoj C; Iaboni S; Saladini I; Castilletti C; Matusali G; Donno DR; Marchioni L; Ianniello S; Corpolongo A; Palange M; Ciliberto G; Piaggio G; De Marco F
Front Immunol; 2021; 12():690322. PubMed ID: 34497602
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.
Diago-Sempere E; Bueno JL; Sancho-López A; Rubio EM; Torres F; de Molina RM; Fernández-Cruz A; de Diego IS; Velasco-Iglesias A; Payares-Herrera C; Flecha IC; Avendaño-Solà C; Palomino RD; Ramos-Martínez A; Ruiz-Antorán B
Trials; 2021 Jan; 22(1):70. PubMed ID: 33472681
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
Benner SE; Patel EU; Laeyendecker O; Pekosz A; Littlefield K; Eby Y; Fernandez RE; Miller J; Kirby CS; Keruly M; Klock E; Baker OR; Schmidt HA; Shrestha R; Burgess I; Bonny TS; Clarke W; Caturegli P; Sullivan D; Shoham S; Quinn TC; Bloch EM; Casadevall A; Tobian AAR; Redd AD
J Infect Dis; 2020 Nov; 222(12):1974-1984. PubMed ID: 32910175
[TBL] [Abstract][Full Text] [Related]
35. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.
Yuan Y; Yu L; Jin Z; Wang Y; Gao M; Ding H; Zhuo X; Zhu X; Gao F; Zheng X; Ying G; Xu X; Kong Q; Lu S; Lv H
Front Cell Infect Microbiol; 2021; 11():650487. PubMed ID: 33796489
[TBL] [Abstract][Full Text] [Related]
36. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
Front Immunol; 2021; 12():613502. PubMed ID: 33968017
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.
Gaborit B; Vanhove B; Vibet MA; Le Thuaut A; Lacombe K; Dubee V; Ader F; Ferre V; Vicaut E; Orain J; Le Bras M; Omnes A; Berly L; Jobert A; Morineau-Le Houssine P; Botturi K; Josien R; Flet L; Degauque N; Brouard S; Duvaux O; Poinas A; Raffi F;
Trials; 2021 Mar; 22(1):199. PubMed ID: 33750432
[TBL] [Abstract][Full Text] [Related]
38. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response).
De Santis GC; Calado RT
Emerg Infect Dis; 2022 May; 28(5):1083-1084. PubMed ID: 35447061
[No Abstract] [Full Text] [Related]
39. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.
Focosi D; Franchini M
Expert Rev Vaccines; 2022 Jul; 21(7):877-884. PubMed ID: 34015243
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
